Innoviva (INVA) Operating Margin (2011 - 2026)
Innoviva's (INVA) quarterly Operating Margin came in at 38.94% in Q1 2026, down 781.0% YoY from 5.72% in Q1 2025, and up 103.06% on a QoQ basis from 1274.01% in Q4 2025.
Innoviva (INVA) Operating Margin (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 16 years of Operating Margin data on file, last reported at 38.94% in Q1 2026.
- Quarterly Operating Margin fell 781.0% year-over-year to 38.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 39.88% (down 595.0% YoY) and the FY2025 annual result came in at 39.81%, down 671.0% from the prior year.
- Operating Margin grew to 38.94% in Q1 2026, from 1274.01% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 58.45% in Q3 2023 to a low of 1274.01% in Q4 2025.
- A 5-year average of 434.34% and a median of 430.5% in 2023 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin tumbled 411120 bps — and 2024, when it surged 116203 bps.
- Tracing INVA's Operating Margin over 5 years: stood at 982.68% in 2022, then surged by 56 bps to 430.5% in 2023, then slumped by 98 bps to 853.36% in 2024, then sank by 49 bps to 1274.01% in 2025, then soared by 103 bps to 38.94% in 2026.
- The last three Operating Margin figures came in at 38.94% (Q1 2026), 1274.01% (Q4 2025), and 42.05% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 42.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.52% |
| Mar 31, 2026 | 38.94% |
| Dec 31, 2025 | -1,274.01% |
| Sep 30, 2025 | 42.05% |
| Jun 30, 2025 | 48.61% |
| Mar 31, 2025 | 46.74% |
| Dec 31, 2024 | -853.36% |
| Sep 30, 2024 | 46.36% |
| Jun 30, 2024 | 54.74% |
| Mar 31, 2024 | -673.86% |
| Dec 31, 2023 | -430.50% |
| Sep 30, 2023 | 58.45% |
| Jun 30, 2023 | -1,107.29% |
| Mar 31, 2023 | -1,173.47% |
| Dec 31, 2022 | -982.68% |
| Sep 30, 2022 | 27.00% |
| Jun 30, 2022 | -585.27% |
| Mar 31, 2022 | -666.20% |
| Dec 31, 2021 | -611.53% |
| Sep 30, 2021 | 95.21% |